SCHEMBL32669328

SCHEMBL32669328

COc1ccc(CNc2ncncc2C#N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ NR2F2 P24468 1/20 0.51
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ TSHR P16473 5/20 0.48
▸ CYP1A2 P05177 4/20 0.48
▸ CYP3A4 P08684 4/20 0.48
▸ CYP2D6 P10635 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ VNN1 O95497 1/20 0.47
▸ THRB P10828 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ PDE5A O76074 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715696 0.80 NPC1 (0.58) EGFRPOLBNR2F2TSHRCYP1A2
SCHEMBL10875900 0.80 EGFR (0.54) EGFRPOLBNR2F2MEN1KMT2A
SCHEMBL28242264 0.77 EGFR (0.52) EGFRPOLBNR2F2MEN1KMT2A
SCHEMBL1920358 0.77 CYP19A1 (0.48) EGFRMEN1KMT2ATSHRALDH1A1
SCHEMBL16629070 0.76 EGFR (0.54) EGFRPOLBNR2F2MEN1KMT2A
SCHEMBL20489647 0.76 GAA (0.47) EGFRPOLBNR2F2MEN1KMT2A
SCHEMBL32669370 0.76 PDE5A (0.51) EGFRPOLBNR2F2TSHRALDH1A1
SCHEMBL32669313 0.75 CDK1 (0.51) EGFRPOLBNR2F2MEN1KMT2A
SCHEMBL28255605 0.75 TSHR (0.63) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL4726558 0.74 TSHR (0.55) EGFRPOLBNR2F2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034126-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034126-A1 KRAS INHIBITORS KRAS, NRAS, HRAS EGFR 53/4885POLB 2736/4885NR2F2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback